Methods of treating cancer using binding molecules that bind CD137 and PD-L1
AssigneeMerus N.V.
InventorsCecilia Anna Wilhelmina Geuijen, Mark Throsby, Cornelis Adriaan De Kruif, Rinse Klooster, Paulus Johannes Tacken, Ton Logtenberg
Life of this patent
Estimating the term…
Abstract
The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell. The invention also provides binding molecules such as antibodies that comprises at least two antigen binding sites, wherein a first antigen binding site can bind an extracellular part of CD137 and a second antigen binding site can bind an extracellular part of PD-L1.
Claims17
A method for treating cancer in an individual, wherein the individual has PD-L1-expressing cancer cells or neoplastic cells, the method comprising administering to the individual in need thereof an antibody that comprises:
- a first antigen binding site that binds an extracellular part of CD137 and that comprises a heavy chain variable region comprising the complementarity determining regions (CDR) CDR1, CDR2, and CDR3 of SEQ ID NO:
- 129 according to Kabat numbering, and
- a second antigen binding site that binds an extracellular part of PD-L1 and that comprises a heavy chain variable region that comprises the CDR1, CDR2, and CDR3 of SEQ ID NO:
- 212 according to Kabat numbering;
- wherein the first and second antigen binding sites each comprise a common light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO:
- 106 according to IMGT numbering.
Dependencies are inferred from the claim text.